More on MBHS...
More on MBHS…
Did you know???
- More than two
million cases of skin cancer are diagnosed in the United States each year. ( according to American Association of Dermatology) www.aad.org
- Current estimates are that one in five Americans will be diagnosed with skin cancer in their lifetime.
- More than 11,000 Americans die each year from skin cancer, but when detected early, skin cancer can have a cure rate of 99 percent.
- While exposure to the sun is the most common trigger for skin cancer, it is in no way the only one.
Skin Cancer Scanning Ltd. believes SkinScan 650 will enable physicians to diagnose skin cancer at an earlier, most curable stage with fewer false positive biopsies.
This would reduce both treatment costs and the number of unnecessary biopsies, and improve quality of life.
Take a look at these similar companies in the sector: RHHBY Recent Price: $32.54 and ICAD Recent Price: $1.87
MBHS, has potential to be take to a whole new level as this company starts
to take off…
Make sure to read the full report at: http://otcreporter.com/alerts.asp
OTCReporter.com, HotOTCChina.com, OTCPennystockreporter.com,
OTCPennypicks.com, and Chartpenny.com (the “Websites”) are owned by Oceanic
Consulting, LLC ("Oceanic") and Garden State Resources NJ, LLC ("Garden State")
(Oceanic and Garden State are collectively referred to herein as the "LLC
Companies) , both of which are New Jersey limited liability
corporations (the Websites and its owners, the LLC Companies, and their
affiliates, directors and officers and its immediate family members are referred
to in our Disclaimer as "OTCR" or "we" or "us" or "our"). Because we receive
monetary or securities compensation, most often in the form of
common stock (hereafter referred to as the "Shares") for our dissemination of
publicly disseminated information (the “Information”) regarding various issuers
of securities, we disclose our specific compensation herein and in our
individual reports of profiled issuers. The LLC Companies received forty
thousand dollars from a non-affiliate third party shareholder of MBHS Skin
Cancer Scanning Ltd. in return for OTCR’s services to publicly and
electronically disseminate information pertaining to Skin Cancer Scanning Ltd. It is imperative that all readers of the above compenstations disclosure
carefully review our Disclaimer in its entirety, which contains important
information about penny stocks, our operations, the limited nature of the
Information and various risks attendant to the companies that we profile,
including that: (a) we receive our compensation in free trading shares, which we
will sell immediately upon their receipt as well as during the dissemination of
such Information or within hours, days, weeks or months thereafter, or at any
time; as a result, our selling activities will cause significant volatility in
the Issuer’s stock price and/or significantly depress the Issuer’s stock price;
(b) we will buy and sell the Shares in the open market before, during or after
the dissemination of the Information or at any time, which will cause
significant volatility in the Issuer’s stock price and/or significantly depress
or increase the Issuer’s stock price; (c) there is an inherent and actual
conflict of interest that exists between our Readers’ interests and our
interests because we: (i) receive the Shares as compensation for disseminating
the Information and thereafter sell those Shares at any time for monetary gain,
including at the same time the Information is being disseminated or shortly
thereafter or at any time; and (ii) buy and sells the Profiled Company’s shares
in the open market at the same time or before the Information is being
disseminated or shortly after the dissemination of the Information or at any
time. Our gains from sale of the Shares may be substantial.
|
Manage your subscription
|